Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Contrast-induced Nephropathy in High-risk Subjects (PROTECT): a Randomized, Placebo-controlled, Double-blind Single-center Trial

Trial Profile

Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Contrast-induced Nephropathy in High-risk Subjects (PROTECT): a Randomized, Placebo-controlled, Double-blind Single-center Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2018

At a glance

  • Drugs Conestat alfa (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Acronyms PROTECT
  • Most Recent Events

    • 22 Jun 2018 Planned End Date changed from 1 May 2018 to 1 Jul 2018.
    • 22 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 05 Jun 2018 According to a Pharming Group NV media release, the endpoints and potential relevance for further clinical development of this trial will be out-lined in Capital Markets Briefing on 21 June 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top